Holt J A, Jordan V C, Tate A C, Lorincz M A
Br J Obstet Gynaecol. 1983 Aug;90(8):751-8. doi: 10.1111/j.1471-0528.1983.tb09306.x.
A monoclonal antibody (D-547) against human breast cancer oestrogen receptor was used to demonstrate that the oestrogen receptor in ovarian epithelial carcinomata binds [3H]monohydroxytamoxifen. This binding was observed in sedimentation velocity analyses of both cytosol and nuclear compartments. Binding of [3H]monohydroxytamoxifen to the antibody-recognized moiety could be inhibited by diethylstilboestrol or oestradiol, but not by androgen, progestin or corticoid, indicating oestrogen specificity for the binding site. The sedimentation coefficient of the antibody-recognized [3H]monohydroxytamoxifen binding moiety was similar to that when 16 alpha-[125I]iodo-oestradiol was used as the ligand.
一种针对人乳腺癌雌激素受体的单克隆抗体（D - 547）被用于证明卵巢上皮癌中的雌激素受体可结合[3H]单羟基他莫昔芬。在细胞质和细胞核部分的沉降速度分析中均观察到了这种结合。[3H]单羟基他莫昔芬与抗体识别部分的结合可被己烯雌酚或雌二醇抑制，但不能被雄激素、孕激素或皮质激素抑制，这表明结合位点具有雌激素特异性。当使用16α - [125I]碘雌二醇作为配体时，抗体识别的[3H]单羟基他莫昔芬结合部分的沉降系数与之相似。
